# Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Source: https://onco.cc/trials/nct00066703/  
OnCo record `nct00066703` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Tamoxifen and Triptorelin in Breast cancer, run by ETOP IBCSG Partners Foundation, completed.

## Summary

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer is a phase 3 interventional study registered as NCT00066703 by ETOP IBCSG Partners Foundation, with 2672 participants recorded, started 2003-11-03 and reaching its primary completion in 2011-03-11. Interventions recorded: exemestane, tamoxifen, triptorelin. Conditions recorded: Breast Cancer.

Linked to the drug Triptorelin because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-24
- Also known as: TEXT
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00066703
- Phase: 3
- Setting: A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer
- Sponsor: ETOP IBCSG Partners Foundation
- Enrolled: 2672
- Outcomes: Disease-free Survival: T+OFS 87.3% vs E+OFS 91.1%, HR 0.717; Overall Survival: T+OFS 93.3% vs E+OFS 93.4%, HR 0.98

## Sources

- ClinicalTrials.gov NCT00066703: https://clinicaltrials.gov/study/NCT00066703

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Tamoxifen](https://onco.cc/drugs/tamoxifen/), [Triptorelin](https://onco.cc/drugs/triptorelin/)
- companies: [ETOP IBCSG Partners Foundation](https://onco.cc/companies/etop-ibcsg/)

---
JSON: https://onco.cc/api/v1/entities/nct00066703.json